These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37569304)

  • 1. Dysbindin Domain-Containing 1 in Prostate Cancer: New Insights into Bioinformatic Validation of Molecular and Immunological Features.
    Tram VTN; Khoa Ta HD; Anuraga G; Dung PVT; Xuan DTM; Dey S; Wang CY; Liu YN
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
    Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
    Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
    Yang Q; Zeng S; Liu W
    PeerJ; 2023; 11():e15019. PubMed ID: 36949759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis.
    Han X; Long W; Liu Y; Xu J
    Front Surg; 2022; 9():985034. PubMed ID: 36338652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Backbone and side chain resonance assignment of the intrinsically disordered human DBNDD1 protein.
    Wiedemann C; Obika KB; Liebscher S; Jirschitzka J; Ohlenschläger O; Bordusa F
    Biomol NMR Assign; 2022 Oct; 16(2):237-246. PubMed ID: 35474152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration.
    Xu Y; Jiang Q; Liu H; Xiao X; Yang D; Saw PE; Luo B
    J Immunol Res; 2020; 2020():8835393. PubMed ID: 33490290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASPM Is a Prognostic Biomarker and Correlates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.
    Deng T; Liu Y; Zhuang J; Tang Y; Huo Q
    Front Oncol; 2022; 12():632042. PubMed ID: 35515103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
    Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
    Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
    Ma C; Kang W; Yu L; Yang Z; Ding T
    Front Oncol; 2020; 10():590006. PubMed ID: 33363020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates.
    Fan K; Zhang BH; Han D; Sun YC
    BMC Bioinformatics; 2023 Apr; 24(1):149. PubMed ID: 37069494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHMT2 is Associated with Tumor Purity, CD8+ T Immune Cells Infiltration, and a Novel Therapeutic Target in Four Different Human Cancers.
    Usman M; Hameed Y; Ahmad M; Iqbal MJ; Maryam A; Mazhar A; Naz S; Tanveer R; Saeed H; Bint-E-Fatima ; Ashraf A; Hadi A; Hameed Z; Tariq E; Aslam AS
    Curr Mol Med; 2023; 23(2):161-176. PubMed ID: 35023455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
    Liu S; Geng R; Lin E; Zhao P; Chen Y
    Front Genet; 2021; 12():602160. PubMed ID: 33732282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zc3h12d, a Novel of Hypomethylated and Immune-Related for Prognostic Marker of Lung Adenocarcinoma.
    Yang B; Ji LL; Xu HL; Li XP; Zhou HG; Xiao T; Li XH; Gao ZY; Li JZ; Zhang WD; Wang GS; Li MJ
    J Inflamm Res; 2021; 14():2389-2401. PubMed ID: 34163207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma.
    Bian T; Zheng M; Jiang D; Liu J; Sun H; Li X; Liu L; Zhang J; Liu Y
    Cancer Cell Int; 2021 Mar; 21(1):144. PubMed ID: 33653340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.